| title,source,date,link,content | |
| Abbott (ABT) Stock Sinks As Market Gains: What You Should Know,Yahoo Finance,"Sep 10, 2025",https://finance.yahoo.com/news/abbott-abt-stock-sinks-market-215002046.html,"In the latest close session, Abbott (ABT) was down 1.96% at $129.36. This change lagged the S&P 500's 0.3% gain on the day. Meanwhile, the Dow lost 0.48%, and the Nasdaq, a tech-heavy index, added 0.03%. | |
| The maker of infant formula, medical devices and drugs's shares have seen an increase of 0.71% over the last month, not keeping up with the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09%. | |
| Analysts and investors alike will be keeping a close eye on the performance of Abbott in its upcoming earnings disclosure. In that report, analysts expect Abbott to post earnings of $1.3 per share. This would mark year-over-year growth of 7.44%. Meanwhile, our latest consensus estimate is calling for revenue of $11.42 billion, up 7.4% from the prior-year quarter. | |
| ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.15 per share and revenue of $44.68 billion. These results would represent year-over-year changes of +10.28% and +6.5%, respectively. | |
| It is also important to note the recent changes to analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. | |
| Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. | |
| The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Abbott is carrying a Zacks Rank of #3 (Hold). | |
| Looking at its valuation, Abbott is holding a Forward P/E ratio of 25.63. This valuation marks a premium compared to its industry average Forward P/E of 19.01. | |
| It is also worth noting that ABT currently has a PEG ratio of 2.5. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 2.17. | |
| The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 144, positioning it in the bottom 42% of all 250+ industries." | |
| Abbott Laboratories Stock (ABT) Opinions on Q2 Earnings and Guidance Update,Nasdaq,"Jul 20, 2025",https://www.nasdaq.com/articles/abbott-laboratories-stock-abt-opinions-q2-earnings-and-guidance-update,"Recent discussions on X about Abbott Laboratories (ABT) have centered on the company’s latest quarterly earnings and guidance updates. Posts on the platform highlight a mixed reaction to the healthcare giant’s performance, with some noting a strong earnings beat for Q2 driven by robust demand for medical devices. However, there’s notable concern over the lower-than-expected Q3 EPS guidance, which has sparked debates about future growth prospects. | |
| Additionally, chatter on X reflects intrigue over analyst upgrades and the stock’s price movement following a dip attributed to the guidance revision. Some users have pointed out the potential for long-term value in what they describe as a resilient, high-quality business, while others remain cautious due to the near-term outlook. This dynamic has kept the conversation lively and polarized among investors tracking the stock. | |
| Note: This discussion summary was generated from an AI condensation of post data. | |
| Abbott Laboratories Congressional Stock Trading | |
| Members of Congress have traded $ABT stock 10 times in the past 6 months. Of those trades, 6 have been purchases and 4 have been sales. | |
| Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months: | |
| REPRESENTATIVE JEFFERSON SHREVE sold up to $100,000 on 05/12. | |
| on 05/12. REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21. | |
| on 03/03 and 1 sale worth up to on 04/21. REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/20 and 0 sales. | |
| on 03/20 and 0 sales. REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 3 purchases worth up to $45,000 on 02/13, 01/29, 01/28 and 1 sale worth up to $15,000 on 03/06. | |
| on 02/13, 01/29, 01/28 and 1 sale worth up to on 03/06. SENATOR SHELLEY MOORE CAPITO sold up to $15,000 on 02/24. | |
| To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. | |
| Abbott Laboratories Insider Trading Activity | |
| Abbott Laboratories insiders have traded $ABT stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales. | |
| Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months: | |
| To track insider transactions, check out Quiver Quantitative's insider trading dashboard. | |
| Abbott Laboratories Hedge Fund Activity | |
| We have seen 1,357 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,427 decrease their positions in their most recent quarter. | |
| Here are some of the largest recent moves: | |
| To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. | |
| Abbott Laboratories Government Contracts | |
| We have seen $115,838,725 of award payments to $ABT over the last year. | |
| Here are some of the awards which we have have seen pay out the most over the last year: | |
| To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. | |
| Abbott Laboratories Analyst Ratings | |
| Wall Street analysts have issued reports on $ABT in the last several months. We have seen 12 firms issue buy ratings on the stock, and 0 firms issue sell ratings. | |
| Here are some recent analyst ratings: | |
| Wells Fargo issued a ""Overweight"" rating on 07/18/2025 | |
| BTIG issued a ""Buy"" rating on 07/18/2025 | |
| Raymond James issued a ""Outperform"" rating on 07/18/2025 | |
| Jefferies issued a ""Buy"" rating on 07/18/2025 | |
| RBC Capital issued a ""Outperform"" rating on 07/15/2025 | |
| Stifel issued a ""Buy"" rating on 04/17/2025 | |
| Barclays issued a ""Overweight"" rating on 04/17/2025 | |
| To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page. | |
| Abbott Laboratories Price Targets | |
| Multiple analysts have issued price targets for $ABT recently. We have seen 15 analysts offer price targets for $ABT in the last 6 months, with a median target of $145.0. | |
| Here are some recent targets: | |
| Lawrence Biegelsen from Wells Fargo set a target price of $142.0 on 07/18/2025 | |
| on 07/18/2025 Jayson Bedford from Raymond James set a target price of $141.0 on 07/18/2025 | |
| on 07/18/2025 Matthew Taylor from Jefferies set a target price of $145.0 on 07/18/2025 | |
| on 07/18/2025 Marie Thibault from BTIG set a target price of $145.0 on 07/18/2025 | |
| on 07/18/2025 Anthony Petrone from Mizuho set a target price of $135.0 on 07/18/2025 | |
| on 07/18/2025 Shagun Singh from RBC Capital set a target price of $147.0 on 07/15/2025 | |
| on 07/15/2025 David Lewis from Morgan Stanley set a target price of $137.0 on 07/15/2025 | |
| This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies. | |
| This article was originally published on Quiver News , read the full story | |
| The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc." | |
| Is It Time To Buy Abbott Stock Now?,Trefis,"Jul 8, 2025",https://www.trefis.com/stock/abt/articles/568811/is-it-time-to-buy-abbott-stock-now/2025-07-08,"Abbott Laboratories (NYSE:ABT) has significantly outperformed the broader S&P 500 index this year, with its stock price rising 18% compared to the S&P 500’s 6% gain. This strong performance stems from the company’s robust quarterly results and optimistic future projections. Given this recent surge, a natural question arises: Is ABT stock still a worthwhile investment? We believe it is. Our conclusion is based on a comprehensive analysis comparing ABT’s current valuation to its operational performance in recent years, as well as its present and historical financial health. As detailed below, our evaluation of Abbott Laboratories across key parameters—Growth, Profitability, Financial Stability, and Downturn Resilience—demonstrates the company’s strong operating performance and sound financial condition. That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative — having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Separately, see – MSFT Stock To $1,000? | |
| How Does Abbott Laboratories’ Valuation Look vs. The S&P 500? | |
| Going by what you pay per dollar of sales or profit, ABT stock looks slightly expensive compared to the broader market. | |
| Abbott Laboratories has a price-to-sales (P/S) ratio of 5.6 vs. a figure of 3.1 for the S&P 500 | |
| Additionally, the company’s price-to-free cash flow (P/FCF) ratio is 37.3 compared to 20.9 for S&P 500 | |
| And, it has a price-to-earnings (P/E) ratio of 17.7 vs. the benchmark’s 26.9 | |
| How Have Abbott Laboratories’ Revenues Grown Over Recent Years? | |
| Abbott Laboratories’ Revenues have grown marginally over recent years. | |
| Abbott Laboratories has seen its top line decline at an average rate of 0.7% over the last 3 years (vs. increase of 5.5% for S&P 500) | |
| over the last 3 years (vs. increase of 5.5% for S&P 500) Its revenues have grown 4.6% from $40 Bil to $42 Bil in the last 12 months (vs. growth of 5.5% for S&P 500) | |
| from $40 Bil to $42 Bil in the last 12 months (vs. growth of 5.5% for S&P 500) Also, its quarterly revenues grew 7.2% to $11 Bil in the most recent quarter from $10 Bil a year ago (vs. 4.8% improvement for S&P 500) | |
| How Profitable Is Abbott Laboratories? | |
| Abbott Laboratories’ profit margins are higher than most companies in the Trefis coverage universe. | |
| Abbott Laboratories’ Operating Income over the last four quarters was $6.8 Bil, which represents a moderate Operating Margin of 16.3% | |
| Abbott Laboratories’ Operating Cash Flow (OCF) over this period was $8.6 Bil, pointing to a moderate OCF Margin of 20.4% (vs. 14.9% for S&P 500) | |
| (vs. 14.9% for S&P 500) For the last four-quarter period, Abbott Laboratories’ Net Income was $13 Bil – indicating a considerably high Net Income Margin of 31.9% (vs. 11.6% for S&P 500) | |
| Does Abbott Laboratories Look Financially Stable? | |
| Abbott Laboratories’ balance sheet looks strong. | |
| Abbott Laboratories’ Debt figure was $15 Bil at the end of the most recent quarter, while its market capitalization is $233 Bil (as of 7/7/2025). This implies a strong Debt-to-Equity Ratio of 6.3% (vs. 19.4% for S&P 500). [Note: A low Debt-to-Equity Ratio is desirable] | |
| (vs. 19.4% for S&P 500). Cash (including cash equivalents) makes up $8.0 Bil of the $81 Bil in Total Assets for Abbott Laboratories. This yields a moderate Cash-to-Assets Ratio of 9.8% | |
| How Resilient Is ABT Stock During A Downturn? | |
| ABT stock has been more resilient than the benchmark S&P 500 index during some of the recent downturns. Worried about the impact of a market crash on ABT stock? Our dashboard How Low Can Abbott Laboratories Stock Go In A Market Crash? has a detailed analysis of how the stock performed during and after previous market crashes. | |
| Inflation Shock (2022) | |
| ABT stock fell 36.2% from a high of $141.46 on 27 December 2021 to $90.19 on 12 October 2023, vs. a peak-to-trough decline of 25.4% for the S&P 500 | |
| from a high of $141.46 on 27 December 2021 to $90.19 on 12 October 2023, vs. a peak-to-trough decline of for the S&P 500 The stock is yet to recover to its pre-Crisis high | |
| The highest the stock has reached since then is 140.22 on 3 March 2025 and currently trades at around $135 | |
| COVID-19 Pandemic (2020) | |
| ABT stock fell 31.6% from a high of $91.86 on 22 January 2020 to $62.82 on 23 March 2020, vs. a peak-to-trough decline of 33.9% for the S&P 500 | |
| from a high of $91.86 on 22 January 2020 to $62.82 on 23 March 2020, vs. a peak-to-trough decline of for the S&P 500 The stock fully recovered to its pre-Crisis peak by 16 April 2020 | |
| Global Financial Crisis (2008) | |
| ABT stock fell 30.6% from a high of $27.92 on 16 September 2008 to $19.38 on 1 May 2009, vs. a peak-to-trough decline of 56.8% for the S&P 500 | |
| from a high of $27.92 on 16 September 2008 to $19.38 on 1 May 2009, vs. a peak-to-trough decline of for the S&P 500 The stock fully recovered to its pre-Crisis peak by 19 March 2012 | |
| Putting All The Pieces Together: What It Means For ABT Stock | |
| In summary, Abbott Laboratories’ performance across the parameters detailed above are as follows: | |
| Growth: Neutral | |
| Profitability: Strong | |
| Financial Stability: Strong | |
| Downturn Resilience: Strong | |
| Overall: Strong | |
| Abbott exhibits strong performance across key financial metrics. While its current valuation, when compared to the broader market, appears somewhat elevated, it remains consistent with the stock’s historical average of 5 times trailing revenues. Furthermore, in comparison to peers like Boston Scientific (trading at 9 times trailing revenues) and Stryker (at 6 times), Abbott’s valuation is competitive. | |
| We believe a premium to Abbott’s historical valuation multiple is warranted. This is driven by the continued market share gains of its FreeStyle Libre platform and the positive impact of recent product launches, including Lingo, TriClip, and i-STAT. | |
| However, it’s crucial to acknowledge potential risks. Investors may be hesitant to assign a higher multiple given the uncertain macroeconomic conditions, particularly with recent developments such as President Trump imposing 25% tariffs on certain trading partners, including Japan and South Korea, effective August 1, 2025. Additionally, the company’s revenue growth has been tempered recently due to declining demand for COVID-19 testing. Therefore, prospective investors should carefully consider these risks before making an investment decision in ABT stock. See, there always remains a meaningful risk when investing in a single, or just a handful, of stocks. Consider the Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics. | |
| Invest with Trefis Market-Beating Portfolios | |
| See all Trefis Price Estimates" | |
| Abbott (ABT) Stock Dips While Market Gains: Key Facts,Nasdaq,"Jun 16, 2025",https://www.nasdaq.com/articles/abbott-abt-stock-dips-while-market-gains-key-facts-0,"In the latest close session, Abbott (ABT) was down 1.19% at $134.01. This move lagged the S&P 500's daily gain of 0.94%. Meanwhile, the Dow gained 0.75%, and the Nasdaq, a tech-heavy index, added 1.52%. | |
| Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 0.61% lagged the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67%. | |
| Investors will be eagerly watching for the performance of Abbott in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.25, showcasing a 9.65% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $11.04 billion, showing a 6.38% escalation compared to the year-ago quarter. | |
| For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.16 per share and a revenue of $44.66 billion, signifying shifts of +10.49% and +6.47%, respectively, from the last year. | |
| Investors should also pay attention to any latest changes in analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. | |
| Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. | |
| The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Abbott possesses a Zacks Rank of #3 (Hold). | |
| Investors should also note Abbott's current valuation metrics, including its Forward P/E ratio of 26.3. This expresses a premium compared to the average Forward P/E of 18.54 of its industry. | |
| Investors should also note that ABT has a PEG ratio of 2.56 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.25. | |
| The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 37% of all 250+ industries. | |
| The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. | |
| Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. | |
| Don’t Miss Out on These Stocks | |
| Before you make your next investing move, we have a free report that highlights the %%CTA_TEXT%% to buy. | |
| Our experts at Zacks Investment Research hand-selected these stocks for their eye-opening growth projections. | |
| Since 1988, our stock picks have more than doubled the S&P 500 with an average gain of +23.89% per year using the Zacks Rank stock-rating system. | |
| Register now to see the %%CTA_TEXT%%. | |
| Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report | |
| Abbott Laboratories (ABT) : Free Stock Analysis Report | |
| This article originally published on Zacks Investment Research (zacks.com). | |
| Zacks Investment Research | |
| The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc." | |
| How Will Abbott Laboratories Stock React To Its Upcoming Earnings?,Trefis,"Apr 14, 2025",https://www.trefis.com/stock/abt/articles/564131/how-will-abbott-laboratories-stock-react-to-its-upcoming-earnings/2025-04-14,"Abbott Laboratories (NYSE:ABT) is scheduled to report its earnings on Wednesday, April 16, 2025. Analysts anticipate earnings of $1.07 per share on sales of $10.41 billion for the first quarter. This represents an increase compared to the prior-year quarter, which saw earnings of $0.98 per share on sales of $9.96 billion. The company’s diabetes product, Freestyle Libre, is expected to be a key driver of this sales growth. | |
| Abbott currently has a market capitalization of $220 billion, with a revenue of $42 billion and operating profits of $6.8 billion over the last twelve months, resulting in a net income of $13 billion. While the stock’s reaction to the upcoming earnings will depend on how the results and outlook compare to investor expectations, historical data from the past five years shows that ABT stock has dropped one day post earnings 60% of the time, with a median fall of 2.4% and a maximum negative return of -6.5%. | |
| This historical trend can be valuable for event-driven traders, who might either position themselves before the announcement based on these odds or analyze the correlation between immediate and medium-term returns to potentially enter a trade the day after the earnings release. That said, if you seek upside with lower volatility than individual stocks, the Trefis High-Quality portfolio presents an alternative – having outperformed the S&P 500 and generated returns exceeding 91% since its inception. | |
| See earnings reaction history of all stocks | |
| Abbott Laboratories’ Historical Odds Of Positive Post-Earnings Return | |
| Some observations on one-day (1D) post-earnings returns: | |
| There are 20 earnings data points recorded over the last five years, with 8 positive and 12 negative one-day (1D) returns observed. In summary, positive 1D returns were seen about 40% of the time. | |
| and one-day (1D) returns observed. In summary, positive 1D returns were seen about 40% of the time. Notably, this percentage increases to 50% if we consider data for the last 3 years instead of 5. | |
| Median of the 8 positive returns = 3.5%, and median of the 12 negative returns = -2.4% | |
| Additional data for observed 5-Day (5D), and 21-Day (21D) returns post earnings are summarized along with the statistics in the table below. | |
| Correlation Between 1D, 5D, and 21D Historical Returns | |
| A relatively less risky strategy (though not useful if the correlation is low) is to understand the correlation between short-term and medium-term returns post earnings, find a pair that has the highest correlation, and execute the appropriate trade. For example, if 1D and 5D show the highest correlation, a trader can position themselves “long” for the next 5 days if 1D post-earnings return is positive. Here is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns. | |
| Learn more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), to produce strong returns for investors. Separately, if you want upside with a smoother ride than an individual stock like Abbott Laboratories, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception. | |
| Invest with Trefis Market-Beating Portfolios | |
| See all Trefis Price Estimates" | |
| ABT Stock Quote Price and Forecast,CNN,"Feb 8, 2024",https://www.cnn.com/markets/stocks/ABT,"Nov 29, 2022 | |
| 7:05am ET | |
| NOTICE For Investors In ABT: Lawsuit against Abbott Laboratories announced by Shareholders Foundation | |
| Oct 31, 2022 | |
| 12:40pm ET | |
| ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline | |
| Oct 30, 2022 | |
| 10:37am ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 30, 2022 | |
| 8:23am ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 28, 2022 | |
| 5:56pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 27, 2022 | |
| 7:14pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 27, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (ABT) | |
| Oct 26, 2022 | |
| 7:06pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 25, 2022 | |
| 5:47pm ET | |
| DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 31, 2022 in Abbott Lawsuit - ABT | |
| Oct 24, 2022 | |
| 6:45pm ET | |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT | |
| Oct 24, 2022 | |
| 4:40pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 23, 2022 | |
| 1:01pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 21, 2022 | |
| 4:22pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 21, 2022 | |
| 12:44pm ET | |
| ABT FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Abbott Laboratories Investors With Losses Over $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT | |
| Oct 20, 2022 | |
| 5:43pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 20, 2022 | |
| 3:48pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Oct 20, 2022 | |
| 1:39pm ET | |
| Moore Kuehn, PLLC Encourages Abbott Laboratories Investors to Contact Law Firm | |
| Oct 20, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (ABT) | |
| Oct 19, 2022 | |
| 5:39pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 19, 2022 | |
| 2:06pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Oct 17, 2022 | |
| 5:48pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 16, 2022 | |
| 5:55pm ET | |
| ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline | |
| Oct 16, 2022 | |
| 1:51pm ET | |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT | |
| Oct 16, 2022 | |
| 8:41am ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 14, 2022 | |
| 10:06pm ET | |
| ROSEN, A TOP RANKED FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT | |
| Oct 13, 2022 | |
| 5:43pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 13, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (ABT) | |
| Oct 12, 2022 | |
| 8:03pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 11, 2022 | |
| 7:53pm ET | |
| ROSEN, Leading Investor Counsel, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Oct 11, 2022 | |
| 7:48pm ET | |
| DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 31, 2022 in Abbott Lawsuit - ABT | |
| Oct 09, 2022 | |
| 7:59pm ET | |
| ROSEN, Top Ranked Investor Counsel, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Oct 08, 2022 | |
| 5:32pm ET | |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abbott Laboratories - ABT | |
| Oct 07, 2022 | |
| 11:33am ET | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending | |
| Oct 06, 2022 | |
| 10:30pm ET | |
| ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline | |
| Oct 06, 2022 | |
| 5:43pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 06, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (ABT) | |
| Oct 05, 2022 | |
| 10:00pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Oct 05, 2022 | |
| 5:39pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 04, 2022 | |
| 12:35pm ET | |
| ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline | |
| Oct 03, 2022 | |
| 5:48pm ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 03, 2022 | |
| 12:17pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Oct 03, 2022 | |
| 10:36am ET | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending | |
| Oct 02, 2022 | |
| 8:41am ET | |
| Abbott Laboratories Deadline Alert | |
| Oct 01, 2022 | |
| 11:00am ET | |
| ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Sep 30, 2022 | |
| 5:10pm ET | |
| ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline | |
| Sep 29, 2022 | |
| 4:58pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Sep 29, 2022 | |
| 4:39pm ET | |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT | |
| Sep 29, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (ABT) | |
| Sep 28, 2022 | |
| 5:39pm ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 28, 2022 | |
| 4:55pm ET | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys Before October Application Deadline in Securities Fraud Class Action | |
| Sep 26, 2022 | |
| 5:48pm ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 25, 2022 | |
| 8:41am ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 24, 2022 | |
| 11:15am ET | |
| ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Sep 23, 2022 | |
| 9:27pm ET | |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT | |
| Sep 23, 2022 | |
| 5:56pm ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 22, 2022 | |
| 7:15pm ET | |
| ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline | |
| Sep 21, 2022 | |
| 6:25pm ET | |
| Abbott Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 31, 2022 to Discuss Your Rights - ABT | |
| Sep 21, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (ABT) | |
| Sep 20, 2022 | |
| 2:34pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Sep 19, 2022 | |
| 3:15pm ET | |
| ABT INVESTOR NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Sep 19, 2022 | |
| 2:23pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Sep 19, 2022 | |
| 12:38pm ET | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed | |
| Sep 18, 2022 | |
| 8:41am ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 17, 2022 | |
| 7:48pm ET | |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abbott Laboratories - ABT | |
| Sep 16, 2022 | |
| 5:56pm ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 16, 2022 | |
| 3:15pm ET | |
| ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Sep 15, 2022 | |
| 5:57pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Sep 15, 2022 | |
| 9:35am ET | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Deadline Established in Securities Fraud Class Action | |
| Sep 15, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (ABT) | |
| Sep 14, 2022 | |
| 5:46pm ET | |
| DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 31, 2022 in Abbott Lawsuit - ABT | |
| Sep 14, 2022 | |
| 5:39pm ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 14, 2022 | |
| 4:16pm ET | |
| ROSEN, A TOP RANKED FIRM, Encourages Abbott Laboratories Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Sep 13, 2022 | |
| 6:04pm ET | |
| ABT LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Abbott Laboratories | |
| Sep 13, 2022 | |
| 4:36pm ET | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed | |
| Sep 13, 2022 | |
| 3:41pm ET | |
| ABT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 31, 2022 in the Class Action Filed on Behalf of Abbott Laboratories Limited Shareholders | |
| Sep 13, 2022 | |
| 12:32pm ET | |
| ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline | |
| Sep 13, 2022 | |
| 10:18am ET | |
| Abbott Laboratories Stock: Abbott Shareholders Are Encouraged to Contact Kehoe Law Firm, P.C. to Discuss Potential Legal Claims | |
| Sep 13, 2022 | |
| 7:14am ET | |
| ABT LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of ABBOTT LABORATORIES Shareholders | |
| Sep 13, 2022 | |
| 1:20am ET | |
| INVESTOR NOTICE: Abbott Laboratories Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ABT | |
| Sep 12, 2022 | |
| 7:15pm ET | |
| SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Abbott Laboratories of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 31, 2022 - (ABT) | |
| Sep 12, 2022 | |
| 5:48pm ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 12, 2022 | |
| 3:12pm ET | |
| ABT LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Abbott Laboratories | |
| Sep 12, 2022 | |
| 11:58am ET | |
| ABT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 31, 2022 in the Class Action Filed on Behalf of Abbott Laboratories Limited Shareholders | |
| Sep 12, 2022 | |
| 9:20am ET | |
| SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm | |
| Sep 12, 2022 | |
| 7:07am ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Sep 11, 2022 | |
| 11:15am ET | |
| ROSEN, A RESPECTED AND LEADING FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Sep 11, 2022 | |
| 8:41am ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 09, 2022 | |
| 6:03pm ET | |
| Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT | |
| Sep 09, 2022 | |
| 5:56pm ET | |
| Abbott Laboratories Deadline Alert | |
| Sep 09, 2022 | |
| 10:50am ET | |
| INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm | |
| Sep 08, 2022 | |
| 9:15pm ET | |
| ABT INVESTOR NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT | |
| Sep 08, 2022 | |
| 10:46am ET | |
| SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm | |
| Sep 08, 2022 | |
| 7:05am ET | |
| DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 31, 2022 in Abbott Lawsuit - ABT | |
| Sep 08, 2022 | |
| 1:45am ET | |
| ABBOTT LABORATORIES (ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Abbott Laboratories (ABT) | |
| Sep 07, 2022 | |
| 10:45am ET | |
| SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm | |
| Sep 06, 2022 | |
| 7:15pm ET | |
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Abbott Laboratories | |
| Sep 06, 2022 | |
| 3:10pm ET | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Infant Formula-Related Securities Fraud Class Action Filed | |
| Sep 06, 2022 | |
| 10:40am ET | |
| SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm | |
| Sep 05, 2022 | |
| 8:40am ET | |
| INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm | |
| Sep 02, 2022 | |
| 11:10pm ET | |
| EQUITY ALERT: Rosen Law Firm Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT" | |
| ABT Stock Price and Chart — NYSE:ABT,TradingView,"Jul 19, 2017",https://www.tradingview.com/symbols/NYSE-ABT/,"Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL. | |
| Show more" | |
| Investors | Stocks and Financial Information,Abbott,"Jan 4, 2016",https://www.abbott.com/investors.html,"Abbott Hosts Conference Call for Third-Quarter Earnings | |
| Abbott Hosts Conference Call for Second-Quarter Earnings | |
| Abbott Hosts Conference Call for First-Quarter Earnings | |
| Abbott Hosts Conference Call for Fourth-Quarter Earnings | |
| An overview of our business, including our financial profile and public honors. | |
| An overview of our business, including our financial profile and public honors. | |
| View current and historic stock information. | |
| View current and historic stock information. | |
| Receive Abbott financial or press release information by email. | |
| Receive Abbott financial or press release information by email. | |
| Abbott’s three most recent annual reports, including proxy statements. | |
| Abbott’s three most recent annual reports, including proxy statements. | |
| To request information via mail, please follow this link. | |
| To request information via mail, please follow this link. | |
| Meet the leadership team and learn about each leader’s role and background. | |
| Meet the leadership team and learn about each leader’s role and background. | |
| Learn how to contact our transfer agent and investor relations department. | |
| Learn how to contact our transfer agent and investor relations department. | |
| Learn about our leadership, governance guidelines and business conduct. | |
| Learn about our leadership, governance guidelines and business conduct. | |
| Abbott's Global Sustainability Report shares how we're focused on helping more people, now and in the years ahead. | |
| Our 2030 Sustainability Plan has a clear priority: designing our life-changing technologies for access and affordability | |
| Abbott takes the top spot on the 2023 Dow Jones Sustainability Index (DJSI) for the 11th year. | |
| © 2025 Abbott. All Rights Reserved. Please read the Legal Notice for further details. | |
| Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. | |
| Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. | |
| The website you have requested also may not be optimized for your specific screen size." | |
| Abbott Laboratories (ABT): Exploring Valuation After a Recent Share Price Pullback,Yahoo Finance,2 weeks ago,https://finance.yahoo.com/news/abbott-laboratories-abt-exploring-valuation-121303428.html,"Abbott Laboratories (ABT) stock has drifted slightly lower this month, with shares showing a 7% drop over the past month. However, year to date, the company has delivered an 11% gain, reflecting underlying strength in its business. | |
| See our latest analysis for Abbott Laboratories. | |
| After a steady climb earlier this year, Abbott Laboratories’ share price momentum has cooled off a bit, with the recent 1-month share price return of -7% standing out against an otherwise solid 11% year-to-date gain. Over the long term, the company keeps delivering for shareholders, posting a 10% total return over the past year and more than 38% over three years, signaling enduring confidence in its healthcare portfolio despite short-term dips. | |
| If Abbott’s performance has you thinking about what’s next in healthcare, there is a whole world of medical leaders to discover. See the full list for free. | |
| With shares now trading more than 14% below the average analyst price target, investors are left to wonder if Abbott Laboratories is undervalued at current levels or if the market is already factoring in expectations for future growth. | |
| Most Popular Narrative: 12.5% Undervalued | |
| Compared to Abbott Laboratories’ latest closing price, this narrative suggests the company is trading at a notable discount to its calculated fair value. The current valuation is built from a thorough analysis of future growth opportunities and potential headwinds. | |
| The expansion of healthcare access and rising middle class in key emerging markets (such as India, China, Latin America, and the Middle East) is fueling robust growth in branded generics and biosimilars, highlighted by Abbott's record sales in these regions and imminent biosimilar launches. This trend is poised to drive sustained double-digit top-line growth and greater geographic revenue diversification. | |
| Read the complete narrative. | |
| Want to know what underpins this optimistic price target? There is one bold financial forecast driving this valuation. Hint: a profit outlook typically reserved for fast-growing innovators. The narrative’s projections go beyond today’s headlines. Curious which future numbers make all the difference here? Discover the financial blueprint behind the discount and see for yourself why some think the market is missing the story. | |
| Result: Fair Value of $144.40 (UNDERVALUED) | |
| Have a read of the narrative in full and understand what's behind the forecasts. | |
| However, ongoing regulatory changes and global pricing pressures could challenge Abbott’s growth outlook. These factors may make long-term earnings less predictable for investors." | |
| Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock,Yahoo Finance,3 weeks ago,https://finance.yahoo.com/news/know-beyond-why-abbott-laboratories-130003926.html,"Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. | |
| Shares of this maker of infant formula, medical devices and drugs have returned -6.1% over the past month versus the Zacks S&P 500 composite's +1.1% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 0.2% over this period. Now the key question is: Where could the stock be headed in the near term? | |
| Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. | |
| Revisions to Earnings Estimates | |
| Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. | |
| Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. | |
| Abbott is expected to post earnings of $1.50 per share for the current quarter, representing a year-over-year change of +11.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%. | |
| The consensus earnings estimate of $5.15 for the current fiscal year indicates a year-over-year change of +10.3%. This estimate has remained unchanged over the last 30 days. | |
| For the next fiscal year, the consensus earnings estimate of $5.67 indicates a change of +10.1% from what Abbott is expected to report a year ago. Over the past month, the estimate has remained unchanged. | |
| Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold)." | |